Apellis CSO sells 909 shares to cover tax withholding

Apellis Pharmaceuticals Chief Scientific Officer Pascal Deschatelets reported a small share sale related to tax withholding.

Rhea-AI Filing Summary

Apellis Pharmaceuticals Chief Scientific Officer Pascal Deschatelets reported a small share sale related to tax withholding. On January 20, 2026, he sold 909 shares of Apellis common stock at an average price of $19.7929 per share. The filing explains that these shares were sold to cover taxes due on Restricted Stock Units that vested on January 16, 2026.

After this transaction, Deschatelets beneficially owned 1,157,310 shares of Apellis common stock in direct form. The transaction is reported on a Form 4 as a non-derivative disposition coded "S," indicating an open-market or similar sale.

Insider Trade Summary

Net Seller: 909 shares

Net Sell 1 txn

Insider Deschatelets Pascal

Role Chief Scientific Officer

Sold 909 shs ($18K)

Type	Security	Shares	Price	Value
Sale	Common Stock	909	$19.7929	$18K

Holdings After Transaction: Common Stock — 1,157,310 shares (Direct)

Footnotes (1)

1. F1. This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Apellis (APLS) report for Pascal Deschatelets?

Apellis reported that Chief Scientific Officer Pascal Deschatelets sold 909 shares of common stock on January 20, 2026, as disclosed on a Form 4.

What was the purpose of Pascal Deschatelets' January 20, 2026 share sale at Apellis (APLS)?

The filing states the 909 shares were sold to cover tax withholding on Restricted Stock Units that were released on January 16, 2026.

At what price were the Apellis (APLS) shares sold by Pascal Deschatelets?

The 909 Apellis common shares sold by Pascal Deschatelets on January 20, 2026 were disposed of at an average price of $19.7929 per share.

How many Apellis (APLS) shares does Pascal Deschatelets own after this transaction?

Following the reported sale, Pascal Deschatelets beneficially owned 1,157,310 shares of Apellis common stock in direct ownership form.

What role does Pascal Deschatelets hold at Apellis (APLS)?

Pascal Deschatelets is an officer of Apellis Pharmaceuticals, serving as the company's Chief Scientific Officer, according to the Form 4.

What transaction code was used for Pascal Deschatelets' Apellis (APLS) share sale?

The sale of 909 Apellis shares by Pascal Deschatelets was reported with transaction code "S" for a non-derivative sale of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 04:16 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Deschatelets Pascal

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S(1)		909	D	$19.7929	1,157,310	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2026.

	/s/ David Watson, attorney-in-fact for Pascal Deschatelets	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.